Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Changing treatment news

Show

From To
HIV Regimen Switch May Contribute to Weight Gain

According to results of a study presented at IDWeek 2017, an increase in body weight is common in HIV patients who are switched from efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC) to an integrase strand transfer inhibitor.

Published
09 October 2017
From
Monthly Prescribing Reference
Terrence Higgins Trust and BHIVA advise on the use of generic HIV antiretroviral therapy

We believe that people living with HIV should be at the heart of decisions made about their care. Therefore decisions around switching to generic HIV medication should be based on a full discussion between a person living with HIV and their HIV clinician.

Published
16 August 2017
From
Terrence Higgins Trust
HIV: A therapeutic advance for resource-limited settings

ANRS 12286 MOBIDIP, a clinical trial running in parallel in three countries in sub-Saharan Africa, shows that dual therapy with lamivudine and a boosted protease inhibitor is effective as second-line treatment in patients infected by HIV with multiple mutations. Such treatment deescalation will reduce costs, side effects, and the need for virological monitoring of patients. The results of this study are published in The Lancet HIV.

Published
31 May 2017
From
Eurekalert Inf Dis
GlaxoSmithKline’s New Drug Challenges HIV Treatment Orthodoxy

GlaxoSmithKline PLC’s ViiV Healthcare announced positive phase-three trial results for its new HIV drug in a dual-drug regimen, supporting the company’s audacious bet that it can shift the treatment orthodoxy away from three-drug combinations.

Published
20 December 2016
From
Wall Street Journal
Ask A Pharmacist: With a new tenofovir, should you switch to Descovy, Genvoya or Odefsey?

I’ve heard more than a few patients ask, what should I do? If I’m already taking Complera, Stribild or Truvada, should I switch to the newer drug formulation with tenofovir alafenamide (TAF)?

Published
20 September 2016
From
BETA blog
Frontier Biotech's Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial

Frontier Biotechnologies Inc. today reported that a phase 3 clinical trial (TALENT Study) of its lead product albuvirtide meets primary objective based on an interim analysis. The results demonstrated that once-weekly given albuvirtide plus ritonavir-boosted lopinavir was non-inferior to WHO-recommended second-line three-drug regimen (control) at 48-week in treatment experienced HIV-1 infected adults. In addition, patients administered with albuvirtide showed statistically better renal safety than those taking the control regimen containing tenofovir disoproxil fumarate.

Published
07 June 2016
From
Frontier Biotech press release
HIV and drug resistance

A recent study found more resistance to the antiretroviral medicine tenofovir than had previously been reported, with 20% resistance to tenofovir in patients with treatment failure in Europe and over 50% resistance in patients with treatment failure in sub-Saharan Africa... The study underlines the importance of rapidly identifying treatment failure through routine measurement of viral load suppression—this is the basis of the third pillar of UNAIDS’ 90–90–90 treatment target, that 90% of people accessing HIV treatment have suppressed viral loads.

Published
09 February 2016
From
UNAIDS
Undetectable & Low-level HIV Viral Replication

Even people who are adherent to their medication regimens may experience occasional “blips” in their viral loads, experience viral rebound or maintain a steady, if low, viral load above undetectable levels. To understand why some people struggle to achieve or remain undetectable, we spoke with Keith Henry, MD, an HIV specialist at Hennepin County Medical Center who has more than 25 years of experience caring for people with HIV.

Published
06 January 2016
From
BETA blog
Study: Protease Inhibitor Monotherapy Does Not Limit Future Treatment Options

A recent study published in The Lancet HIV provides evidence that HIV maintenance therapy with a provider-selected boosted protease inhibitor (PI) regimen does not increase the risk of drug resistance and thus preserves future treatment options. But questions remain as to whether PI-monotherapy could be a clinically useful and relevant long-term HIV maintenance strategy.

Published
10 December 2015
From
BETA blog
Study shows effectiveness of switching antiretroviral therapy for HIV-infected children

A Columbia University study evaluated whether HIV-infected children in South Africa who had achieved viral suppression with one antiretroviral treatment could transition to efavirenz-based therapy, the recommended drug for children older than three years, without risk of viral failure. The researchers reported that the treatment program resulted in excellent sustained virological control.

Published
06 November 2015
From
Eurekalert Inf Dis
← First12345Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.